335 related articles for article (PubMed ID: 12100080)
1. Bone remodelling markers and serum cytokines in patients with hyperthyroidism.
Akalin A; Colak O; Alatas O; Efe B
Clin Endocrinol (Oxf); 2002 Jul; 57(1):125-9. PubMed ID: 12100080
[TBL] [Abstract][Full Text] [Related]
2. Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy.
Barsal G; Taneli F; Atay A; Hekimsoy Z; Erciyas F
Tohoku J Exp Med; 2004 Jul; 203(3):183-8. PubMed ID: 15240927
[TBL] [Abstract][Full Text] [Related]
3. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
4. Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism.
Simsek G; Karter Y; Aydin S; Uzun H
Chin J Physiol; 2003 Dec; 46(4):181-6. PubMed ID: 15074839
[TBL] [Abstract][Full Text] [Related]
5. Early changes in parameters of bone and mineral metabolism during therapy for hyper- and hypothyroidism.
Sabuncu T; Aksoy N; Arikan E; Ugur B; Tasan E; Hatemi H
Endocr Res; 2001; 27(1-2):203-13. PubMed ID: 11428712
[TBL] [Abstract][Full Text] [Related]
6. Bone turnover in hyperthyroidism before and after thyrostatic management.
Isaia GC; Roggia C; Gola D; Stefano MD; Gallone G; Aimo G; Ardissone P; Mussetta M
J Endocrinol Invest; 2000 Dec; 23(11):727-31. PubMed ID: 11194705
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokines in thyrotoxicosis.
Siddiqi A; Monson JP; Wood DF; Besser GM; Burrin JM
J Clin Endocrinol Metab; 1999 Feb; 84(2):435-9. PubMed ID: 10022397
[TBL] [Abstract][Full Text] [Related]
8. Effects of treatment of hyperthyroidism on glucose homeostasis, insulin secretion, and markers of bone turnover.
Al-Shoumer KA; Vasanthy BA; Al-Zaid MM
Endocr Pract; 2006; 12(2):121-30. PubMed ID: 16690458
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin and bone metabolism markers in hyperthyroidism before treatment and interrelations between them.
Sarıtekin İ; Açıkgöz Ş; Bayraktaroğlu T; Kuzu F; Can M; Güven B; Mungan G; Büyükuysal Ç; Sarıkaya S
Acta Biochim Pol; 2017; 64(4):597-602. PubMed ID: 29059259
[TBL] [Abstract][Full Text] [Related]
10. Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients.
Langdahl BL; Loft AG; Eriksen EF; Mosekilde L; Charles P
Thyroid; 1996 Jun; 6(3):169-75. PubMed ID: 8837322
[TBL] [Abstract][Full Text] [Related]
11. Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy.
Langdahl BL; Loft AG; Eriksen EF; Mosekilde L; Charles P
Thyroid; 1996 Jun; 6(3):161-8. PubMed ID: 8837321
[TBL] [Abstract][Full Text] [Related]
12. Markers of bone turnover in hyperthyroidism and the effects of treatment.
Garnero P; Vassy V; Bertholin A; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Apr; 78(4):955-9. PubMed ID: 8157727
[TBL] [Abstract][Full Text] [Related]
13. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
14. Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis.
Nagasaka S; Sugimoto H; Nakamura T; Kusaka I; Fujisawa G; Sakuma N; Tsuboi Y; Fukuda S; Honda K; Okada K; Ishikawa S; Saito T
Clin Endocrinol (Oxf); 1997 Aug; 47(2):215-21. PubMed ID: 9302397
[TBL] [Abstract][Full Text] [Related]
15. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
[TBL] [Abstract][Full Text] [Related]
16. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.
Pantazi H; Papapetrou PD
J Clin Endocrinol Metab; 2000 Mar; 85(3):1099-106. PubMed ID: 10720046
[TBL] [Abstract][Full Text] [Related]
17. [The influence of hyperthyroidism and glucocorticosteroid treatment on bone metabolism in patients with Graves' disease and ophthalmopathy].
Kaźmierczyk-Puchalska A; Kulig G; Krzyzanowska-Swiniarska B; Pilarska K
Endokrynol Pol; 2005; 56(3):259-64. PubMed ID: 16350719
[TBL] [Abstract][Full Text] [Related]
18. Serum cytokines and bone metabolism in patients with thyroid dysfunction.
Sekeroglu MR; Altun ZB; Algün E; Dülger H; Noyan T; Balaharoglu R; Oztürk M
Adv Ther; 2006; 23(3):475-80. PubMed ID: 16912030
[TBL] [Abstract][Full Text] [Related]
19. Biochemical bone markers in patients with multiple myeloma.
Nawawi H; Samson D; Apperley J; Girgis S
Clin Chim Acta; 1996 Sep; 253(1-2):61-77. PubMed ID: 8879839
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment.
Celik I; Akalin S; Erbaş T
Eur J Endocrinol; 1995 Jun; 132(6):668-72. PubMed ID: 7788003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
